Adverse Obstetric Outcomes in Gestational Diabetes Mellitus and Inositol Stereoisomears
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 120
- 主要终点
- OGTT result
研究概览
简要总结
Comparison of different inositol stereoisomears in preventing adverse obstetric outcomes in non-obese pregnant women at high risk for gestational diabetes mellitus.
详细描述
The investigators compared outcomes from metabolic and obstetric point of view in GDM pregnant non-obese patient with different stereoisomears of inositol supply. Dietary control and placebo or inositol steroisomears were administered starting at the enrolling time (first fasting oral glucose above 92 mg%; usually before 20 weeks gestations') till the delivery and/or pregnancy end/termination. Oral glucose tolerance test results at 24-28 weeks' gestation was evaluated (as glucose values and oGTT screening). Fetal growth, delivery data, obstetric outcomes and necessity of insulin therapy were taken into account.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 45 Years(Adult)
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •pregnancy below 20 weeks gestation BMI below 30 Fasting glucose between 92 and 126 mg% Singleton pregnancy Naturally conceived
排除标准
- •obese patient Fasti g glucose above 126 or below 92
结局指标
主要结局
OGTT result
时间窗: 24-28 weeks' gestation
OGTT is the mainstay of obstetric outcomes in GDM
次要结局
- Fetal measurements at third trimester(28 weeks)
- Adverse obstetric outcome(from first elevated oral fasting glucose (above 92 mg%) till the end/termination of pregnancy (latter 42 weeks gestation))
- Delivery data(25-42 weeks gestations')
研究者
Claudio Celentano
MD
G. d'Annunzio University
